SMSbiotech
SMSBiotech is a San Diego-based biotech company dedicated to revolutionizing regenerative medicine through the discovery and application of a novel human stem cell, the Small Mobile Stem (SMS) cell. Founded in 2015, the company leverages proprietary, patented technology to develop off-the-shelf cell therapies aimed at addressing the root causes of chronic and age-related diseases, with a focus on tissue regeneration, bio-manufacturing, and cost-effective medical solutions. With a team of leading scientists, medical professionals, and business experts, SMSBiotech aims to change how the life science industry approaches cell and drug development, ultimately improving patient outcomes and longevity.
Industries
Nr. of Employees
small (1-50)
SMSbiotech
San Marcos, California, United States, North America
Patents
Products
Allogeneic off-the-shelf adult therapeutic cells
Human adult-derived allogeneic therapeutic cells produced at scale for use in regenerative medicine applications; described as immuno-tolerant, robust, and suitable for off-the-shelf administration.
Cell-derived extracellular matrix protein products
Therapeutic and research-grade extracellular matrix and matrisome protein preparations derived from cultured therapeutic cells for use in tissue reconstruction and regeneration.
SMS Cell
Essential matrisomal and other extracellular matrix proteins derived from human Small Mobile Stem Cells, supporting tissue reconstruction and vascular induction.
SMS Cell Therapy for COPD
Small Mobile Stem (SMS) cell therapy targeting respiratory care and chronic obstructive pulmonary disease (COPD), currently in Phase I clinical trials.
Small Mobile Stem
A first-in-class regenerative medicine platform utilizing proprietary human allogeneic adult Small Mobile Stem (SMS) cells derived from adult human blood for the treatment of degenerative diseases such as COPD.
Small Mobile Stem Cells
Human Small Mobile Stem (SMS) cells developed as a cutting-edge, allogeneic, off-the-shelf adult stem cell technology designed for safe and affordable regenerative medicine.
Allogeneic off-the-shelf adult therapeutic cells
Human adult-derived allogeneic therapeutic cells produced at scale for use in regenerative medicine applications; described as immuno-tolerant, robust, and suitable for off-the-shelf administration.
Cell-derived extracellular matrix protein products
Therapeutic and research-grade extracellular matrix and matrisome protein preparations derived from cultured therapeutic cells for use in tissue reconstruction and regeneration.
SMS Cell
Essential matrisomal and other extracellular matrix proteins derived from human Small Mobile Stem Cells, supporting tissue reconstruction and vascular induction.
SMS Cell Therapy for COPD
Small Mobile Stem (SMS) cell therapy targeting respiratory care and chronic obstructive pulmonary disease (COPD), currently in Phase I clinical trials.
Small Mobile Stem
A first-in-class regenerative medicine platform utilizing proprietary human allogeneic adult Small Mobile Stem (SMS) cells derived from adult human blood for the treatment of degenerative diseases such as COPD.
Small Mobile Stem Cells
Human Small Mobile Stem (SMS) cells developed as a cutting-edge, allogeneic, off-the-shelf adult stem cell technology designed for safe and affordable regenerative medicine.
Services
Scale-up and production of human allogeneic therapeutic cells and cell-derived proteins for research and therapeutic applications.
Design and execution of proof-of-concept efficacy studies and animal safety/toxicology evaluations relevant to degenerative diseases.
Development and application of in vitro functional potency assays and QC workflows to validate manufacturing lots and predict in vivo performance.
Scale-up and production of human allogeneic therapeutic cells and cell-derived proteins for research and therapeutic applications.
Design and execution of proof-of-concept efficacy studies and animal safety/toxicology evaluations relevant to degenerative diseases.
Development and application of in vitro functional potency assays and QC workflows to validate manufacturing lots and predict in vivo performance.
Expertise Areas
- Regenerative medicine
- Cellular biomanufacturing (scale-up)
- Preclinical development and pipeline management
- Safety and toxicology testing
Key Technologies
- Adult stem cell isolation and expansion
- Allogeneic off-the-shelf cell therapy manufacturing
- Extracellular matrix (matrisome) protein production
- Industrial-scale cell biomanufacturing